Liver function tests in children and adolescents receiving risperidone treatment for a year: A longitudinal, observational study from Turkey a

International Journal of Psychiatry in Clinical Practice

Volumn 15, Issue 3, 2011, Pages 204-208

  Karaman, Mehmet Gökşin ^a   Erdoǧan, Ayten ^b   Tufan, Evren ^c   Yurteri, Nihal ^b   Özdemir, Esra ^b   Ankarali, Handan ^d  

^a MALTEPE UNIVERSITY   (Turkey)

^b Zonguldak Karaelmas Universitesi Tip Fakultesi   (Turkey)

^c Elazig Hospital for Mental Disorders   (Turkey)

^d DUZCE UNIVERSITY   (Turkey)

Author keywords

Adolescents; ALP; ALT; Antipsychotics; AST; Children; Liver function tests; Risperidone

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; RISPERIDONE;

ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CHILD; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; LIVER FUNCTION TEST; LONG TERM CARE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; SIDE EFFECT; TURKEY (REPUBLIC);

ADOLESCENT; BILIRUBIN; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; LIVER DISEASES; LIVER FUNCTION TESTS; LONGITUDINAL STUDIES; MALE; OBSERVATION; RISPERIDONE; TIME FACTORS; TURKEY;

EID: 84860391792     PISSN: 13651501     EISSN: 14711788     Source Type: Journal    
DOI: 10.3109/13651501.2011.582537     Document Type: Article

References (25)

1. Olfson M, Blanco C, Liu L, Moreno C, Laje G. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry 2006; 63(6):679-85.
2. Erdogan A, Kocabasoglu N, Yalug I, Ozbay G, Senturk H. Management of marked liver enzyme increase during clozapine treatment: A case report and review of the literature. Int J Psychiatry Med 2004;34(1):83-9.
3. Shirzadi AA, Ghaemi SN. Side effects of atypical antipsychotics: Extrapyramidal symptoms and the metabolic syndrome. Harv Rev Psychiatry 2006;14(3):152-64.
4. Wu RR, Zhao JP, Liu ZN, Zhai JG, Guo XF, Guo WB, et al. Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in fi rstepisode schizophrenia. Psychopharmacology 2006;186(4): 572-8.
5. Correll CU, Carlson HE. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry 2006;45(7): 771-91.
6. Fleischhaker C, Heiser P, Hennighausen K, Herpertz- Dahlmann B, Holtkamp K, Mehler-Wex C, et al. Weight gain associated with clozapine, olanzapine and risperidone in children and adolescents. J Neural Trans 2007;114(2):273-80.
7. Penzner JB, Dudas M, Saito E, Olshanskiy V, Parikh UH, Kapoor S, et al. Lack of effect of stimulant combination with second-generation antipsychotics on weight gain, metabolic changes, prolactin levels, and sedation in youth with clinically relevant aggression or oppositionality. J Child Adolesc Psychopharmacol 2009;19(5):563-73.
8. Ratzoni G, Gothelf D, Brand-Gothelf A, Reidman J, Kikinzon L, Gal G, et al: Weight gain associated with olanzapine and risperidone in adolescent patients: A comparative prospective study. J Am Acad Child Adolesc Psychiatry 2002;41: 337-43.
9. Panagiotopoulos C, Ronsley R, Davidson J. Increased prevalence of obesity and glucose intolerance in youth treated with second-generation antipsychotic medications. Can J Psychiatry 2009;54(11):743-9.
10. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during fi rsttime use in children and adolescents. J Am Med Assoc 2009;302(16):1765-73.
11. Woods SW, Martin A, Spector SG, McGlashan TH. Effects of development on olanzapine-associated adverse events. J Am Acad Child Adolesc Psychiatry 2002;41(12):1439-46.
12. Gonzalez-Heydrich J, Raches D, Wilens TE, Leichtner A, Mezzacappa E. Retrospective study of hepatic enzyme elevations in children treated with olanzapine, divalproex, and their combination. J Am Acad Child Adolesc Psychiatr 2003;42(10):1227-33.
13. Sikich L, Frazier JA, McClellan J, Findling RL, Vitiello B, Ritz, L, et al. Double-blind comparison of fi rst- and secondgeneration antipsychotics in early-onset schizophrenia and schizo-affective disorder: Findings from the treat treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatr 2008;165(11):1420-31.
14. Panagiotopoulos C, Ronsley R, Elbe D, Davidson J, Smith DH. First do no harm: Promoting an evidence-based approach to atypical antipsychotic use in children and adolescents. J Can Acad Child Adolesc Psychiatry 2010;19(2): 124-37.
15. Erdogan A, Karaman MG, Ozdemir E, Yurteri N, Tufan AE, Kurcer MA. Six months of treatment with risperidone may be associated with non-signifi cant abnormalities of liver function tests in children and adolescents: A longitudinal, observational study from Turkey. J Child Adolesc Psychopharmacology 2010;20(5):407-13
16. Malone RP, Maislin G, Choudhury MS, Gi fford C, Delaney MA. Risperidone treatment in children and adolescents with autism: Short- and long-term safety and effectiveness. J Am Acad Child Adolesc Psychiatry 2002;41(2): 140-7.
17. Zuddas A, Di Martino A, Muglia P, Cianchetti C. Long-term risperidone for pervasive developmental disorder: Effi cacy, tolerability, and discontinuation. J Child Adolesc Psychopharmacol 2000;10(2):79-90.
18. Turgay A, Binder C, Snyder R, Fisman S: Long-term safety and effi cacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics 2002;110:e34.
19. Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 2004;114:e634-41.
20. Erdogan A, Atasoy N, Akkurt H, Ozturk D, Karaahmet E, Yalug I, et al. Risperidone and liver function tests in children and adolescents: A short-term prospective study. Progress NeuroPsychopharmacol Biol Psychiatr 2008; 32(3):849-57.
21. Pae CU, Lim HK, Kim TS, Kim JJ, Lee CU, Lee SJ, et al. Naturalistic observation on the hepatic enzyme changes in patients treated with either risperidone or olanzapine alone. Int Clin Psychopharmacol 2005;20(3):173-6.
22. Garcia-Unzueta MT, Herran A, Sierra-Biddle D, Amado JA, Vazquez-Barquero JL, Alvarez C. Alterations of liver function test in patients treated with antipsychotics. J Clin Lab Anal 2003;17(6):216-8.
23. Kumra S, Herion D, Jacobsen LK, Briguglia C, Grothe D. Case study: Risperidone-induced hepatotoxicity in pediatric patients. J Am Acad Child Adolesc Psychiatry 1997;36(5): 701-5.
24. Szigethy E, Wiznitzer M, Branicky LA, Maxwell K, Findling RL. Risperidone-induced hepatotoxicity in children and adolescents? A chart review study. J Child Adolesc Psychopharmacol 1999;9(2):93-8.
25. Schatzberg AF. Safety and tolerability of antidepressants: Weighing the impact on treatment decisions. J Clin Psychiatry 2007;68(Suppl 8):26-34.